About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Multiple Myeloma (MM) Quality of Life (QOL) Study | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNNCT04388735

Multiple Myeloma (MM) Quality of Life (QOL) Study

The main purpose of this study is to examine differences in quality of life and psychological distress for both Multiple Myeloma patients receiving treatment and their caregivers and to assess patient...

Lead sponsor: Massachusetts General Hospital•3 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

Elizabeth K O'Donnell, MD

CONTACT

617-643-2517 ekodonnell@mgh.harvard.edu

Sponsors

Lead Sponsor

Massachusetts General Hospital

Collaborators

Kully Family Foundation

This research study's procedures include screening for eligibility, participant designation of a caregiver and a series of questionnaires. \- It is expected that about 180 people undergoing treatment for multiple myeloma and up to 180 of their caregivers will take part in this research study. \-- The questionnaires are completed one time only and measure quality of life, mood, coping strategies, and prognostic understanding and can be completed in the hospital, clinic, over the email, or telephone with assistance provided as needed.Questionnaires take approximately 20 minutes to complete.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patient Eligibility criteria:
•Adult patients (greater than 18 years) receiving active therapy for MM.
•* For patients with newly diagnosed MM, patients are eligible while undergoing induction therapy prior to received autologous stem cell transplant but not after.
•Ability to read questions in English or willing to complete questionnaires with the assistance of an interpreter.
•Caregiver Eligibility criteria:
•Adult (greater than 18 years) relative or a friend of a patient who agrees to participate in the study whom the patient identified as living with them or having in-person contact with him or her at least twice per week.
•Ability to read and respond to questions in English or to complete questionnaires with minimal assistance of an interpreter

Exclusion Criteria

•* Patients receiving maintenance therapy only.
•* Significant psychiatric or other co-morbid disease, which the treating clinician believes prohibits informed consent or participation in the study.

Related studies

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

NCT07249528 · Non-hodgkin Lymphoma, Multiple Myeloma

RECRUITINGPhase 2

Lysergic Acid Diethylamide (LSD) in Palliative Care

NCT05883540 · Palliative Care, Pain, and more

RECRUITINGPhase 1

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

NCT06215118 · Multiple Myeloma

Male Experiences With Intra Cytoplasmic Sperm Injection (ICSI) and Reduced Sperm Quality

NCT07546435 · Psychological Experience in Fertility Treatment, Hypogonadism, and more

RECRUITINGPhase 3

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

NCT06679101 · Multiple Myeloma, Newly Diagnosed Multiple Myeloma

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 14, 2020Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment360

Start dateJun 2020

Last updatedMay 14, 2020

Condition

Multiple Myeloma Quality of Life Symptom, Behavioral

Locations shown

Massachusetts General Hospital Cancer Center

Boston, Massachusetts

Beth Israel Deaconess Medical Center

Boston, Massachusetts

Dana-Farber Cancer Institute

Boston, Massachusetts

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 14, 2020Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions